Siege Pharmaceuticals - A Kairos Ventures Portfolio Company

Company Summary

Siege Pharmaceuticals is developing new cancer drugs based on a naturally-occurring molecule that starves cancer cells to death. Our drugs are synthetic variants with optimized drug-like properties. By targeting multiple pathways that cancer cells need for growth, it is intended that cancers will be unable to develop resistance, a common challenge with most cancer therapies. The company’s programs are currently at the preclinical stage.

Year Founded:  2018

Key Executives:
• Daniel Gil, CEO
• Aimee Edinger, President and Founder

Location:  Irvine, CA

Company Status:  Private

Year Invested:  2019

Investment Status:  Current

Board Member:  Pascal Krotee, PhD